{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q16552",
      "entity_text" : "IL-17",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00112",
      "entity_text" : "brodalumab",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The antagonism of IL-17 signaling by brodalumab was initially proven effective in inducing clinical, histologic, and genomic resolution of psoriasis after only 1 week of treatment in a phase I, proof-of-concept study enrolling 10 patients with psoriasis [XREF_BIBR].",
  "reading_complete" : "2020-08-04T12:55:23Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-04T12:49:02Z",
  "trigger" : "signaling",
  "evidence" : [ "IL-17 signaling by brodalumab" ],
  "pmc_id" : "4065277",
  "score" : 0
}